S. Helle

发表

Alpha emitter radium-223 and survival in metastatic prostate cancer.

I Syndikus, J Kliment, S. Fosså, 2013, The New England journal of medicine.

Statistical motion modelling for robust evaluation of clinically delivered accumulated dose distributions after curative radiotherapy of locally advanced prostate cancer.

B. Heijmen, L. Muren, M. Söhn, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer

P. Lønning, H. Adlercreutz, S. Helle, 2005, Breast Cancer Research and Treatment.

Small Cell Lung Cancer in a 14-Year-Old Girl

H. Sorbye, H. K. Haugland, S. Helle, 2012, Journal of pediatric hematology/oncology.

Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin‐like growth factors and IGF binding proteins 1 and 3: a cross‐over study

P. Lønning, J. Holly, S. Helle, 1996, Clinical endocrinology.

The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids

P. Lønning, J. Holly, S. Helle, 2002, The Journal of Steroid Biochemistry and Molecular Biology.

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

M. Kattan, C. Parker, S. Nilsson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking.

P. Lønning, J. Geisler, S. Helle, 1999, The Journal of endocrinology.

684 RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES A PHASE III RANDOMIZED TRIAL (ALSYMPCA)

C. Parker, N. James, P. Hoskin, 2012 .

130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

S. Fosså, C. Parker, N. James, 2012 .

Alterations in the insulin-like growth factor system during the menstrual cycle in normal women.

P. Lønning, G. Anker, J. Holly, 1998, Maturitas.

The insulin-like growth factor system in advanced breast cancer.

S. Helle, 2004, Best practice & research. Clinical endocrinology & metabolism.

The n e w e n g l a n d j o u r n a l of m e d i c i n e Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

S. Fosså, D. Bottomley, J. Logue, 2022 .

Insulin-like growth factors in breast and prostatic cancer

P. Lønning, S. Helle, 1995 .

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

S. Fosså, C. Parker, N. James, 2017, European urology.

The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy.

P. Lønning, S. Frøland, T. Ueland, 2001, The Journal of clinical endocrinology and metabolism.

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer

P. Lønning, J. Geisler, G. Anker, 2001, British Journal of Cancer.

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

M. Kattan, C. Parker, S. Nilsson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.

C. Parker, N. Vogelzang, J. O’Sullivan, 2013 .

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

S. Fosså, C. Parker, N. James, 2014, The Lancet. Oncology.

Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).

S. Fosså, C. Parker, N. James, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients

P. Lønning, G. Anker, M. Tally, 1996, The Journal of Steroid Biochemistry and Molecular Biology.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Sten Nilsson, Oliver Sartor, John Logue, 2014, The Lancet. Oncology.

Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.

P. Lønning, J. Klijn, L. Ottestad, 2005, European journal of cancer.

Insulin-like growth factors in breast cancer.

P. Lønning, S. Helle, P. Lønning, 1996, Acta oncologica.

Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.

P. Lønning, J. Geisler, J. Holly, 1998, British Journal of Cancer.

Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.

O. Odland, L. Muren, L. Hysing, 2008, International journal of radiation oncology, biology, physics.

A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer

S. Knappskog, C. Beisland, O. Halvorsen, 2023, Cancer Immunology, Immunotherapy.

Effects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependency.

S. Geisler, P. Lønning, S. Lundgren, 1999, European journal of cancer.

Influence of treatment with tamoxifen and change in tumor burden on the IGF‐system in breast cancer patients

P. Lønning, M. Tally, J. Holly, 1996, International journal of cancer.

Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).

S. Fosså, C. Parker, N. James, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relations between sex hormones, sex hormone binding globulin, insulin‐like growth factor‐I and insulin‐like growth factor binding protein‐I in post‐menopausal breast cancer patients

P. Lønning, H. Adlercreutz, G. Anker, 1995, Clinical endocrinology.

A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer.

C. Beisland, O. Halvorsen, K. Kalland, 2020 .

Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer

O. Halvorsen, R. Kvåle, Yngve Nygård, 2019, Advances in radiation oncology.

Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer‐specific mortality. A population‐based study of 13 198 patients

S. Fosså, B. Møller, R. Kvåle, 2019, The Prostate.

The Prostate

S. Fosså, B. Møller, R. Kvåle, 2019 .

Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma

P. Lønning, S. Lundgren, E. Diamandis, 1999, Cancer.

Influence of treatment with onapristone on the IGF-system in breast cancer patients

P. Lønning, W. Jonat, J. Holly, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.

M. Alber, L. Muren, L. Hysing, 2008, International Journal of Radiation Oncology, Biology, Physics.

Cardiovascular outcomes after curative prostate cancer treatment: A population-based cohort study

T. Bjørge, K. Bønaa, R. Kvåle, 2023, Frontiers in Oncology.

Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer

T. Aas, S. Geisler, P. Lønning, 2001, British Journal of Cancer.

Prediction of rectum and bladder morbidity following radiotherapy of prostate cancer based on motion-inclusive dose distributions.

Ludvig Paul Muren, Maria Thor, L. Muren, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

IGF-1 and breast cancer.

P. Lønning, S. Helle, 2004, Novartis Foundation symposium.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

101 Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) and bone metastases

C. Parker, D. Heinrich, S. Helle, 2013 .

Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases

N. James, S. Nilsson, A. Widmark, 2013 .

Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up

R. Kvåle, L. Hysing, S. Helle, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.